Victory Capital Management Inc. lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 22.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 94,750 shares of the company's stock after selling 27,478 shares during the quarter. Victory Capital Management Inc. owned approximately 0.21% of Pacira BioSciences worth $1,785,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its stake in Pacira BioSciences by 16.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock valued at $9,462,000 after buying an additional 70,307 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Pacira BioSciences by 11.8% during the 4th quarter. Bank of New York Mellon Corp now owns 396,399 shares of the company's stock valued at $7,468,000 after acquiring an additional 41,881 shares in the last quarter. Impax Asset Management Group plc lifted its stake in Pacira BioSciences by 14.8% during the fourth quarter. Impax Asset Management Group plc now owns 540,027 shares of the company's stock worth $10,174,000 after purchasing an additional 69,424 shares during the last quarter. Ieq Capital LLC acquired a new position in Pacira BioSciences in the fourth quarter worth $291,000. Finally, Principal Financial Group Inc. increased its stake in Pacira BioSciences by 4.2% during the fourth quarter. Principal Financial Group Inc. now owns 257,733 shares of the company's stock valued at $4,856,000 after purchasing an additional 10,306 shares during the last quarter. Institutional investors own 99.73% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price target for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC upped their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Finally, HC Wainwright increased their target price on Pacira BioSciences from $57.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $27.22.
Read Our Latest Stock Report on PCRX
Pacira BioSciences Price Performance
Shares of NASDAQ:PCRX traded up $0.28 during trading on Friday, reaching $24.10. The company had a trading volume of 522,462 shares, compared to its average volume of 905,444. The firm's fifty day moving average is $24.37 and its 200 day moving average is $19.49. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm has a market capitalization of $1.12 billion, a PE ratio of -11.87 and a beta of 0.86. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67.
Pacira BioSciences Profile
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
See Also
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
